📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-03 17:31
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
25 announcements match the current filters (relevance ≥ 5).
20% Revenue Growth in Q1 FY27; Capacity Expansion to 54,000 MTPA Nears Completion
Privi Speciality Chemicals reported a strong start to FY27 with total income rising 20.01% YoY to Rs 681.42 Cr. The company maintained resilient EBITDA margins at 24.58%, supported by volume growth and price increases. A key milestone is the imminent commercialization of Phase-1 capacity expansion, increasing total capacity from 48,000 to 54,000 MTPA. Additionally, the PRIGIV JV is scaling up with a planned Rs 50 Cr equity infusion to support 42 exclusive products for Givaudan.
Confidence: HIGH
What changedThe company has moved from planning to the final stages of its Phase-1 capacity expansion and has officially filed the merger scheme with NCLT following stock exchange approvals.
Why it mattersThe expansion and sustained 25% margins demonstrate strong execution in a volatile chemical market, while the PRIGIV JV provides high-margin, exclusive revenue streams from a global leader like Givaudan.
Q1 Total Income: Rs 681.42 CrEBITDA Margin: 24.58%Target Capacity: 54,000 MTPAJV Equity Infusion: Rs 50 CrQ1 PAT Growth: 35.37%
📅 Short termThe stock may react positively to the margin resilience and the nearing completion of the Phase-1 capacity expansion, which provides immediate volume growth visibility.
📈 Long termThe '5K, 1K' vision (Rs 5,000 Cr revenue) and the introduction of 10 advanced specialty products like Maltol suggest a structural shift towards higher-value chemistry and larger scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Volatility in crude-derivative input costs
- Geopolitical risks affecting global supply chains
- Execution risk for Phase 2 and 3 expansion projects
Key Highlights
Total consolidated income grew 20.01% YoY to Rs 681.42 Cr in Q1 FY27.
Phase-1 capacity expansion to 54,000 MTPA (up from 48,000 MTPA) is expected to be commercialized shortly.
EBITDA margins sustained at 24.58%, marking nine consecutive quarters of approximately 25% margins.
Profit After Tax (PAT) rose to Rs 83.2 Cr, a significant increase from Rs 61.46 Cr in Q1 FY26.
PRIGIV JV to receive Rs 50 Cr additional equity infusion for its next phase of expansion.
👀 What to Watch
Investors should monitor the exact commercialization date of the 6,000 MTPA capacity addition and the progress of the NCLT merger process for group entities, expected to conclude within FY27.
36% PAT Growth in Q1 FY27; Privi Speciality Reaffirms Rs 5,000 Cr Revenue Vision
Privi Speciality Chemicals reported a strong start to FY27, with Q1 total income rising 20.01% YoY to Rs 681.42 Cr. Net Profit (PAT) surged 35.97% YoY to Rs 84.21 Cr, driven by broad-based demand and operational efficiencies. Despite a one-off fire incident at a warehouse costing Rs 2.78 Cr (impacting margins by 42 bps), EBITDA margins remained robust at 24.58%. The company is aggressively pursuing its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA by FY29-30.
Confidence: HIGH
What changedThe company reported strong Q1 FY27 results and provided an updated roadmap for its '5K, 1K' vision, indicating a clear path to doubling revenue over the next 3-4 years.
Why it mattersThe results demonstrate strong operational leverage and the ability to maintain margins despite external shocks (fire incident). The improving debt-to-EBITDA ratio and ROCE indicate a strengthening balance sheet and efficient capital allocation.
Q1 FY27 Revenue: Rs 681.42 CrQ1 Revenue vs TTM Revenue: 26.57%EBITDA Margin: 24.58%Net Debt to EBITDA: 1.29xVision 2030 Revenue Target: Rs 5,000 CrFire Loss Impact: Rs 2.78 Cr
📅 Short termThe stock is likely to react positively to the strong earnings growth and margin expansion, reflecting healthy demand in the aroma chemicals segment.
📈 Long termThe structural shift towards high-end speciality molecules and the Givaudan partnership (PRIGIV) position the company for sustained growth towards its FY30 targets.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- One-off fire loss at warehouse
- Volatility in crude-derivative raw material prices
- Execution risk for expansion projects slated for 2028
Key Highlights
Total income grew 20.01% YoY to Rs 681.42 Cr in Q1 FY27.
Net Profit increased by 35.97% YoY to Rs 84.21 Cr.
EBITDA margin stood at 24.58%, showing resilience despite a Rs 2.78 Cr fire loss.
Net Debt to EBITDA ratio significantly improved to 1.29x from 2.57x in FY24.
ROCE improved by 299 bps YoY to 21.70% in Q1 FY27.
👀 What to Watch
Monitor the execution of the PRIGIV JV and the progress of expansion projects slated for commercial operations in H2 2028. Investors should also track the proposed amalgamation with Privi Fine Sciences for potential synergy benefits.
Privi Speciality Files Amalgamation Scheme with NCLT; Recommends ₹10 Final Dividend
Privi Speciality Chemicals has formally filed its Scheme of Amalgamation with the NCLT Mumbai Bench as of June 25, 2026, to merge two subsidiaries into the parent entity. The Board also approved the Q1 FY27 financial results and reiterated a final dividend recommendation of ₹10 per share for FY26. The total dividend payout of ₹39.06 Cr represents approximately 12.3% of the company's TTM PAT of ₹316 Cr. This move follows the receipt of observation letters from NSE and BSE in early May 2026.
Confidence: HIGH
What changedThe company has progressed from receiving exchange observations to the legal filing stage with the NCLT for its internal corporate restructuring.
Why it mattersThe amalgamation of subsidiaries is intended to simplify the corporate structure and potentially streamline operations within its core Aroma Chemicals segment.
Final Dividend: ₹10 per shareTotal Dividend Payout: ₹39.06 CrDividend vs TTM PAT: ~12.3%NCLT Filing Date: June 25, 2026
📅 Short termThe stock may see minor interest due to the dividend recommendation, though the market will focus on the specific Q1 FY27 performance figures once fully analyzed.
📈 Long termThe structural consolidation via amalgamation and the '5K, 1K' vision (targeting ₹5,000 Cr revenue) remain the key long-term value drivers.
⚠ Risk flags
- Regulatory and legal delays in the NCLT approval process for the amalgamation
Key Highlights
Filed Scheme of Amalgamation with NCLT Mumbai on June 25, 2026, for merging two entities.
Recommended a final dividend of ₹10 per equity share for the financial year ended March 31, 2026.
Total dividend payout aggregates to ₹3,906.27 lakhs (₹39.06 Cr).
Received regulatory observation letters from NSE and BSE on May 5 and May 6, 2026, respectively.
The merger involves Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited.
👀 What to Watch
Monitor the NCLT approval timeline for the merger and the upcoming 41st Annual General Meeting for the final dividend approval and record date.
Privi Speciality Chemicals Q1 FY27 Results; Amalgamation Filed with NCLT
Privi Speciality Chemicals approved its unaudited Q1 FY27 results for the period ended June 30, 2026. The company has formally filed its Scheme of Amalgamation for Privi Fine Sciences and Privi Biotechnologies with the NCLT Mumbai Bench as of June 25, 2026. A final dividend of Rs 10 per share for FY26, totaling Rs 39.06 Cr, is pending shareholder approval. The company continues to pursue its '5K, 1K' vision, targeting Rs 5,000 Cr revenue and Rs 1,000 Cr EBITDA over the next 3-4 years.
Confidence: HIGH
What changedThe company has progressed its internal merger from the regulatory observation stage to a formal NCLT filing.
Why it mattersThe amalgamation of biotech and fine science arms into the main entity simplifies the corporate structure and aligns with the long-term goal of reaching Rs 5,000 Cr in revenue.
Final Dividend: Rs 10 per shareTotal Dividend Outlay: Rs 39.06 CrDividend vs TTM PAT: ~12.3%NCLT Filing Date: June 25, 2026Target Capacity: 54,000 MTPA
📅 Short termThe stock may see neutral to range-bound movement as the market digests the Q1 earnings performance and the progress of the merger.
📈 Long termStructural growth is tied to the successful integration of the merged entities and the realization of the '5K, 1K' vision through the Givaudan partnership.
⚠ Risk flags
- Volatility in crude oil derivative prices impacting input costs
- Large working capital requirements
- Regulatory delays in NCLT approval for the amalgamation
Key Highlights
Final dividend of Rs 10 per equity share recommended for FY26, aggregating to Rs 3,906.27 lakhs
Scheme of Amalgamation filed with NCLT Mumbai Bench on June 25, 2026
Observation letters for the merger received from NSE and BSE on May 05 and May 06, 2026, respectively
Company targeting capacity expansion to 54,000 MTPA by January 2026
PRIGIV JV ramping up to manufacture 42 exclusive products for Givaudan SA
👀 What to Watch
Monitor the NCLT approval timeline for the amalgamation and the execution of the PRIGIV JV, which is a key driver for the company's high-end product expansion.
₹300 Cr Term Loan Assigned [ICRA]AA (Stable) Rating by ICRA
ICRA Limited has assigned a new long-term rating of [ICRA]AA with a Stable outlook to Privi Speciality Chemicals' ₹300 crore term loan from ICICI Bank. This rated amount represents approximately 41% of the company's current total debt of ₹729 crore and 11.7% of its TTM revenue. The high credit rating reflects the company's strong market position as India's leading aroma chemical manufacturer and its strategic partnership with Givaudan. This assignment provides a solid credit foundation as the company pursues its '5K, 1K' vision of reaching ₹5,000 crore in revenue.
Confidence: HIGH
What changedICRA has formally assigned a high-grade [ICRA]AA rating to a new ₹300 crore term loan facility.
Why it mattersA high credit rating (AA) confirms the company's financial stability and operational strength, ensuring continued access to low-cost capital for its capital-intensive expansion plans.
Rated Term Loan Amount: ₹300 CrAssigned Rating: AAOutlook: StableLoan vs Existing Debt: ~41.1%Loan vs TTM Revenue: ~11.7%
📅 Short termThe news is likely to be viewed positively by the market as it validates the company's creditworthiness and financial health.
📈 Long termThe AA rating supports the company's long-term '5K, 1K' vision by providing the necessary credit profile to fund large-scale expansions and strategic joint ventures like PRIGIV.
⚠ Risk flags
- Increased debt levels if the loan is fully drawn
- Sensitivity to interest rate cycles despite high rating
Key Highlights
ICRA assigned a long-term rating of [ICRA]AA with a Stable outlook.
The rating applies to a specific ₹300 crore fund-based term loan from ICICI Bank.
The rated facility equals ~41.1% of the company's existing debt of ₹729 crore.
The assignment follows a period of strong financial performance with TTM PAT of ₹316 crore and OPM of 25.2%.
👀 What to Watch
Monitor the company's interest expense in future quarters to see if this high credit rating translates into lower borrowing costs. Investors should also track the utilization of this ₹300 crore loan toward the planned capacity expansion to 54,000 MTPA by January 2026.
ICRA Assigns [ICRA]AA (Stable) Rating to Rs 300 Cr Term Loan
ICRA Limited has assigned a new long-term rating of [ICRA]AA with a Stable outlook for Privi Speciality Chemicals' Rs 300 crore term loan from ICICI Bank. This rated facility represents approximately 41% of the company's current total debt of Rs 729 crore and 21% of its net worth. The high credit rating reflects the company's strong market position as India's leading aroma chemical manufacturer and its robust financial profile, including a 26.0% ROCE. This rating assignment facilitates the company's access to competitive capital as it pursues its '5K, 1K' revenue and EBITDA vision.
Confidence: HIGH
What changedICRA has formally assigned a high-grade credit rating to a specific Rs 300 crore term loan facility taken from ICICI Bank.
Why it mattersA high credit rating (AA) validates the company's financial strength and ensures it can borrow at competitive rates, which is crucial for its capital-intensive growth strategy targeting Rs 5,000 Cr revenue.
Rated Amount: Rs 300 CrRating Assigned: [ICRA]AA (Stable)Rated Amount vs Net Worth: 20.86%Rated Amount vs TTM Debt: 41.15%Current Debt: Rs 729 Cr
📅 Short termThe assignment of a high credit rating is likely to be viewed positively by the market as it confirms the company's low credit risk profile.
📈 Long termThe rating supports the company's long-term vision of scaling revenue to Rs 5,000 Cr by providing a solid foundation for debt-funded expansion and maintaining institutional confidence.
⚠ Risk flags
- Interest rate volatility on the new term loan
- Large working capital requirements typical of the chemical industry
Key Highlights
ICRA assigned a new [ICRA]AA rating with a Stable outlook for a Rs 300 crore term loan
The rated amount of Rs 300 crore is significant relative to the existing debt of Rs 729 crore
The facility is a long-term fund-based term loan availed from ICICI Bank Limited
Company maintains a healthy Debt-to-Equity ratio of 0.51 based on latest financials
Rating supports the company's expansion plan to reach 54,000 MTPA capacity by January 2026
👀 What to Watch
Monitor the company's interest coverage ratio and the progress of the PRIGIV JV, as this debt likely supports the capital expenditure required for the 54,000 MTPA capacity expansion.
Privi Speciality Chemicals FY26 PAT Surges 75% to ₹327.5 Cr; Guides for 20% Growth in FY27
Privi Speciality Chemicals delivered a robust performance in FY26, with revenue growing 21.7% to ₹2,582.9 crore and PAT surging 75.2% to ₹327.5 crore. The company maintained strong EBITDA margins of 25.8% and achieved a healthy ROCE of 22.4%. Management has guided for a 20% growth in the coming year and aims to double revenue to ₹5,000 crore within 3-4 years. Additionally, the PRIGIV joint venture turned profitable in Q4, and the company announced a dividend of ₹10 per share.
Key Highlights
FY26 Revenue increased by 21.73% YoY to ₹2,582.92 crore, driven by volume growth and improved product mix.
Net Profit (PAT) for FY26 jumped 75.16% to ₹327.54 crore, with EBITDA margins expanding to 25.76%.
The Board recommended a dividend of ₹10 per share (100% of face value) following strong cash flow generation.
Phase 1 capex expansion to 54,000 MTPA is on track for completion by June 30, 2026.
Management targets ₹5,000 crore revenue and ₹1,000 crore+ EBITDA over the next 3-4 years, representing a 2x growth.
👀 What to Watch
Investors should take note of the strong margin profile and the upcoming capacity expansion as key catalysts for sustained growth. The stock remains attractive given the management's clear roadmap to double revenue and the improving profitability of the Givaudan JV.
Privi Speciality Chemicals FY26 PAT Surges 75% to ₹327.5 Cr; EBITDA Margins Expand to 25.8%
Privi Speciality Chemicals reported a robust performance for FY26, with total income growing 21.7% YoY to ₹2,582.92 crore. Profit After Tax (PAT) witnessed a significant jump of 75.2% to ₹327.54 crore, driven by volume growth and a superior product mix. The company successfully reduced its net debt by ₹113 crore, resulting in a Net Debt to Equity ratio of 0.62x. Notably, the PRIGIV JV with Givaudan turned PAT positive in Q4 FY26 and received a ₹180 crore interest-free trade advance to further deleverage the balance sheet.
Key Highlights
FY26 Revenue increased 21.7% YoY to ₹2,582.92 crore with EBITDA growing 40.3% to ₹665.45 crore.
EBITDA margins expanded by 342 bps to 25.8% for the full year FY26.
Net Debt reduced from ₹1,064.96 crore to ₹886.77 crore, improving the Net Debt/EBITDA ratio to 1.33x.
Return on Capital Employed (ROCE) and Return on Equity (ROE) improved significantly to 22.2% and 24.8% respectively.
The PRIGIV JV achieved a milestone by turning PAT positive in Q4 FY26.
👀 What to Watch
Investors should maintain a positive outlook given the strong margin expansion, debt reduction, and the strategic turnaround of the Givaudan JV. The company's progress toward its '5K:1K' vision (₹5,000 Cr revenue, ₹1,000 Cr EBITDA) suggests continued growth potential.
Privi Speciality Chemicals Declares Rs 10 Dividend and Reports FY26 Annual Results
Privi Speciality Chemicals has announced its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 10 per share (100% of face value), rewarding shareholders for the fiscal year. Key management personnel, including Executive Director Bhaktavatsala Rao Doppalapudi, have been re-appointed for a three-year term to ensure leadership stability. The company has set July 31, 2026, as the record date for dividend payments, which will be finalized following the AGM on August 7, 2026.
Key Highlights
Recommended a final dividend of Rs 10 per equity share (100% of face value) for FY 2025-26.
Approved audited standalone and consolidated financial results for the full year ending March 31, 2026.
Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a 3-year term starting August 13, 2026.
Fixed July 31, 2026, as the record date for determining dividend entitlement.
The 41st Annual General Meeting (AGM) is scheduled for August 7, 2026.
👀 What to Watch
Existing shareholders should hold the stock until the record date of July 31, 2026, to benefit from the 100% dividend payout. The management continuity is a positive sign for long-term strategic execution.
Privi Speciality Chemicals Declares Rs 10 Dividend; Sets July 31, 2026 as Record Date
Privi Speciality Chemicals Limited has recommended a final dividend of Rs. 10 per equity share (100% of face value) for the financial year 2025-26. The company has fixed July 31, 2026, as the record date to determine the eligibility of shareholders for this payout. The board also approved the audited financial results for the year ended March 31, 2026, and scheduled the 41st Annual General Meeting for August 7, 2026. Additionally, the board approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term.
Key Highlights
Recommended a final dividend of Rs. 10 per equity share (100% of face value) for FY 2025-26.
Fixed July 31, 2026, as the Record Date for dividend entitlement.
The 41st Annual General Meeting (AGM) is scheduled to be held on August 7, 2026.
Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years effective August 13, 2026.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock prior to the ex-dividend date, which will be shortly before the July 31 record date. Review the full FY26 earnings report to assess the company's growth trajectory alongside the dividend payout.
Privi Speciality Chemicals Recommends ₹10 Dividend and Approves FY26 Audited Results
Privi Speciality Chemicals (PRIVISCL) has recommended a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26. The Board approved the audited financial results for the year ended March 31, 2026, which received an unmodified opinion from statutory auditors BSR & Co. LLP. Key management decisions include the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term. The company has fixed July 31, 2026, as the record date for dividend entitlement.
Key Highlights
Recommended a final dividend of ₹10 per equity share (100%) for FY 2025-26.
Statutory auditors BSR & Co. LLP issued an unmodified opinion on FY26 financial results.
Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years starting August 2026.
Fixed July 31, 2026, as the record date for dividend entitlement with the AGM set for August 7, 2026.
Re-appointed Aneja Associates as Internal Auditor and Kishore Bhatia & Associates as Cost Auditors for FY 2026-27.
👀 What to Watch
Investors should ensure they hold shares by the record date of July 31, 2026, to be eligible for the ₹10 dividend. The unmodified audit report and continuity in management are positive indicators of corporate governance and stability.
Privi Speciality Chemicals Re-appoints Director, Recommends ₹10 Final Dividend
Privi Speciality Chemicals has recommended a final dividend of ₹10 per share (100% of face value) for FY 2025-26. The Board also approved the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term starting August 2026. Financially, the company's standalone non-current assets grew to ₹1,39,006.99 Lakhs from ₹1,17,952.94 Lakhs year-on-year. The record date for the dividend is set for July 31, 2026, with the AGM scheduled for August 7, 2026.
Key Highlights
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26.
Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years effective August 13, 2026.
Standalone non-current assets increased by approximately 17.8% YoY to ₹1,39,006.99 Lakhs.
Record date for dividend entitlement is fixed as July 31, 2026, with payment within 30 days of the AGM.
👀 What to Watch
Investors should maintain their positions to qualify for the ₹10 dividend before the July 31 record date. The re-appointment of key management indicates operational continuity which is a positive signal for long-term stability.
Privi Speciality Chemicals Recommends Rs. 10 Final Dividend; Sets Record Date for July 31, 2026
Privi Speciality Chemicals Limited has announced a final dividend of Rs. 10 per equity share for the financial year 2025-26, representing a 100% payout on the face value. The board has fixed July 31, 2026, as the record date to determine eligible shareholders for this payout. The dividend is subject to approval at the 41st Annual General Meeting scheduled for August 07, 2026. Additionally, the company approved the re-appointment of its Executive Director for a three-year term starting August 2026.
Key Highlights
Recommended a final dividend of Rs. 10 per equity share (100% of face value) for FY 2025-26
Fixed July 31, 2026, as the record date for determining dividend entitlement
Scheduled the 41st Annual General Meeting (AGM) for Friday, August 07, 2026
Approved re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for 3 years
Audited financial results for the quarter and year ended March 31, 2026, were approved by the Board
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 31, 2026. The 100% dividend payout indicates healthy cash flow and management's commitment to rewarding shareholders.
Privi Speciality Chemicals Recommends Rs 10 Dividend and Approves FY26 Financial Results
Privi Speciality Chemicals has announced its audited financial results for the fiscal year ended March 31, 2026, alongside a significant dividend recommendation. The Board proposed a final dividend of Rs. 10 per equity share (100% of face value), with the record date set for July 31, 2026. Additionally, the company confirmed the re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a three-year term. Financial statements show a notable increase in standalone non-current assets to ₹1,390.07 crore, up from ₹1,179.53 crore in the previous year.
Key Highlights
Recommended a final dividend of Rs. 10 per equity share (100% of face value) for the financial year 2025-26.
Standalone non-current assets grew to ₹1,390.07 crore as of March 31, 2026, compared to ₹1,179.53 crore in 2025.
Re-appointed Mr. Bhaktavatsala Rao Doppalapudi as Executive Director for a 3-year term effective August 13, 2026.
Fixed July 31, 2026, as the record date for determining dividend entitlement.
The 41st Annual General Meeting (AGM) is scheduled for August 07, 2026.
👀 What to Watch
Investors should monitor the full earnings release for margin trends, but the 100% dividend recommendation and asset growth are positive signals. Shareholders must hold the stock before the July 31 record date to be eligible for the Rs. 10 dividend.
Privi Speciality Chemicals Gets BSE No-Objection for Merger with Two Group Entities
Privi Speciality Chemicals Limited (PSCL) has received a 'No Objection' observation letter from BSE Limited regarding its proposed Scheme of Amalgamation. The merger involves absorbing Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into PSCL. This follows a previous clearance from the National Stock Exchange (NSE), marking a significant step in the regulatory approval process. The consolidation, initially approved by the Board in December 2025, aims to streamline the group's speciality chemicals and biotechnology operations.
Key Highlights
Received 'No Objection' observation letter from BSE Limited on May 06, 2026.
Proposed merger involves three entities: PSCL (Transferee), PFSPL (Transferor 1), and PBPL (Transferor 2).
Company has now secured clearances from both major stock exchanges (NSE and BSE).
The Scheme of Amalgamation was originally approved by the Board on December 19, 2025.
Final execution remains subject to NCLT and other statutory/creditor approvals.
👀 What to Watch
Investors should view this as a positive regulatory milestone that brings the company closer to operational consolidation. Monitor future announcements regarding NCLT approval timelines and the potential impact on the company's consolidated financial profile.
Privi Speciality Chemicals Receives NSE No-Objection for Amalgamation Scheme
Privi Speciality Chemicals Limited (PSCL) has received a 'No Objection' observation letter from the National Stock Exchange of India (NSE) regarding its proposed scheme of amalgamation. The scheme involves merging two entities, Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, into PSCL. This follows the initial board approval granted on December 19, 2025, and marks a significant step in the regulatory approval process. While NSE has cleared the proposal, the company is still awaiting a similar observation letter from the BSE.
Key Highlights
Received 'No Objection' observation letter from NSE on May 05, 2026
Scheme involves the merger of Privi Fine Sciences and Privi Biotechnologies into PSCL
Initial board approval for the consolidation was granted on December 19, 2025
Observation letter from BSE is currently awaited to proceed with the next stages of the merger
👀 What to Watch
Investors should view this as a positive step toward corporate consolidation and monitor for the upcoming BSE approval and NCLT filings. The merger is expected to streamline operations, though the final impact on share swap ratios and valuation should be reviewed once the scheme is finalized.
CRISIL Reaffirms Privi Speciality Chemicals' Ratings at AA-/Stable for Rs 1118 Cr Facilities
CRISIL Ratings has reaffirmed the long-term rating of 'CRISIL AA-/Stable' and the short-term rating of 'CRISIL A1+' for Privi Speciality Chemicals Limited. The rating covers total bank loan facilities amounting to Rs. 1,118 crore, which includes fund-based limits, non-fund based limits, and term loans. This reaffirmation reflects the company's maintained credit profile and its ability to service debt across its diverse banking consortium. The 'Stable' outlook indicates that the rating agency expects the company's business and financial risk profile to remain steady in the medium term.
Key Highlights
Long-term credit rating reaffirmed at 'CRISIL AA-/Stable' for bank facilities.
Short-term credit rating reaffirmed at 'CRISIL A1+', the highest rating for short-term debt.
Total bank loan facilities rated amount to Rs. 1,118 crore across multiple major banks.
Major term loan exposure includes Rs. 271 crore from HDFC Bank Limited.
The ratings remain valid until March 31, 2027, subject to continuous surveillance.
👀 What to Watch
The reaffirmation confirms the company's stable financial health and consistent creditworthiness. Investors should view this as a sign of operational stability, though no immediate price action is expected from this routine update.
Privi Speciality Chemicals Invests ₹25.5 Cr in JV with Givaudan; Maintains 51% Stake
Privi Speciality Chemicals Limited has infused ₹25.5 crore into its joint venture company, Prigiv Specialties Private Limited, through a preferential allotment of equity shares. Its global partner, Givaudan SA of Switzerland, also contributed ₹24.5 crore, resulting in a total fresh capital infusion of ₹50 crore into the JV. Following this allotment, the total paid-up capital of the JV has increased to ₹85 crore. Privi Speciality Chemicals continues to hold a majority stake of 51%, while Givaudan holds the remaining 49%.
Key Highlights
Privi Speciality Chemicals subscribed to 2.55 crore equity shares at ₹10 each, totaling ₹25.5 crore.
JV partner Givaudan SA invested ₹24.5 crore for 2.45 crore shares to maintain its 49% stake.
The total paid-up capital of Prigiv Specialties Private Limited rose from ₹35 crore to ₹85 crore.
Privi Speciality Chemicals maintains controlling interest with a 51% shareholding post-allotment.
👀 What to Watch
Investors should view this capital infusion as a positive sign of commitment toward the strategic partnership with global leader Givaudan. This move strengthens the JV's balance sheet for future growth in the high-margin specialty chemicals space.
Privi Speciality Q3 FY26 PAT Surges 84% in 9M; Targets ₹5,000 Cr Revenue in 3-4 Years
Privi Speciality Chemicals reported a robust Q3 FY26 with revenue growing 25% YoY to ₹611.15 crores and EBITDA margins sustaining above 25% for the third consecutive quarter. The company is aggressively pursuing its '5k:1k' vision, aiming for ₹5,000 crores in revenue and ₹1,000 crores in EBITDA within 3-4 years. Operational highlights include a capacity expansion from 48,000 MT to 54,000 MT expected by April 2026 and a strategic debt reduction in the Prigiv JV through interest-free advances from Givaudan. Management expects 11-15% volume growth next year, supported by a favorable trade landscape in the US and Europe.
Key Highlights
9M FY26 adjusted PAT grew by 84% YoY to ₹232 crores, driven by operational efficiencies and product mix.
EBITDA margins remained strong at 25.83% for Q3, with management guiding for a 20-27% range going forward.
Phase 1 capacity expansion to 54,000 MT is on track for commercialization by March/April 2026.
Givaudan to provide non-interest-bearing trade advances to the Prigiv JV to significantly reduce debt and interest costs.
Company plans a 3-phase expansion to increase overall capacity by 55% over the next 2-3 years.
👀 What to Watch
Investors should maintain a positive outlook given the company's consistent margin profile and clear 2x revenue growth roadmap. The strengthening partnership with Givaudan and upcoming capacity additions provide strong earnings visibility for the next 24 months.
Privi Speciality Q3 FY26 PAT Surges 76% YoY to ₹78 Cr; EBITDA Margins Expand to 25.8%
Privi Speciality Chemicals reported a robust Q3 FY26 with consolidated revenue growing 24% YoY to ₹611.15 crore and PAT jumping 76% to ₹77.99 crore. The company's EBITDA margin expanded by 251 bps to 25.83%, driven by operational efficiencies and a higher share of value-added products. Management reaffirmed its '5k:1k' vision, targeting ₹5,000 crore revenue and ₹1,000 crore EBITDA within 3-4 years, supported by a ₹1,200 crore CAPEX plan. Notably, the PRIGIV joint venture turned EBITDA positive during the quarter.
Key Highlights
9M FY26 Consolidated PAT surged 94% YoY to ₹233.84 crore on revenue of ₹1,857.23 crore.
EBITDA margins improved to 25.83% in Q3 FY26, up from 23.32% in the corresponding quarter last year.
Planned CAPEX of ₹1,200 crore over 2-3 years to expand capacity and introduce new speciality molecules.
PRIGIV JV achieved positive EBITDA; Givaudan to provide ₹150 crore trade advance to reduce JV debt.
Net Debt to EBITDA ratio improved significantly to 1.63x (annualized) from 2.25x in FY25.
👀 What to Watch
Investors should take note of the significant margin expansion and the turnaround in the PRIGIV joint venture as key growth drivers. The clear roadmap toward doubling revenue and EBITDA over the next 3-4 years makes this a strong candidate for long-term portfolios.
